Human Gene Therapy Methods Latest Impact Factor* 1.831
Human Gene Therapy Clinical Development Latest Impact Factor* 2.490
Submit to Your Manuscript: Special Issue on Manufacturing and Quality Controll
Sign Up for Our Free eNewsletter: Gene and Cell Therapy Connect
Aims & Scope
Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies. Human Gene Therapy provides a central forum for scientific and clinical information, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.
The Journal is divided into three parts. Human Gene Therapy, the flagship, is published 12 times per year. HGT Methods, a bimonthly journal, focuses on the applications of gene therapy to product testing and development. HGT Clinical Development, a quarterly journal, serves as a venue for publishing data relevant to the regulatory review and commercial development of cell and gene therapy products.
- Improvements in vector developments
- Delivery systems
- Cell therapy
- Small nucleic acid therapeutics, including RNAi
- Clinical trials and animal models
- Clinical protocols
- Pre-clinical animal and in vitro studies to assess the safety of gene and cell therapy products used to support clinical applications
- Clinical trials including those in which the results are confirmatory or negative
- Topical issues related to the commercial development of gene and cell therapy products
Human Gene Therapy was voted one of the most influential journals in Biology and Medicine over the last 100 years by the Biomedical & Life Sciences Division of the Special Libraries Association.
Human Gene Therapy, HGT Methods, and HGT Clinical Development are under the editorial leadership of Editor-in-Chief Terence R. Flotte, MD, University of Massachusetts Medical School; Deput Editors Europe Nathalie Cartier, MD, INSERM, and Thierry VandenDriessche, PhD, Free University of Brussels (VUB); Deputy Editors U.S. Barry J. Byrne, MD, PhD, Powell Gene Therapy Center, University of Florida, College of Medicine and Mark A. Kay, MD, PhD, Stanford University School of Medicine; Human Gene Therapy Editor Guangping Gao, PhD, University of Massachusetts Medical School; Methods Editor Hildegard Büning, PhD, Hannover Medical School; Clinical Development Editor James M. Wilson, MD, PhD, University of Pennsylvania School of Medicine, Gene Therapy Program; and other leading investigators. View the entire editorial board.
Audience: Geneticists, medical geneticists, molecular biologists, virologists, experimental researchers, and experimental medicine specialists, among others.
Human Gene Therapy and HGT Methods provide “Instant Online” publication 72 hours after acceptance
This subscription includes:
Human Gene Therapy is the definitive peer-reviewed rapid-publication journal covering all aspects of human gene therapy. The Journal publishes scientific papers on original investigations into the transfer and expression of genes in mammals, including humans with in-depth coverage of DNA, RNA, and cell therapies. Improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, are covered.
Human Gene Therapy Methods (HGT Methods) publishes technological advances in cell and gene therapy that promote the development of gene therapy products into successful therapeutics. The Journal breaks new ground as the first to exclusively focus on the applications of gene therapy to product testing and development.
Human Gene Therapy Clinical Development publishes data relevant to the regulatory review and commercial development of cell and gene therapy products. Pre-clinical papers focus on pharmacology/toxicity/bio-distribution experiments used in the review of proposed clinical trials and will contain sufficient information to allow referencing between products within the same technology platform when appropriate.
Current Contents®/Life Sciences;
Science Citation Index Expanded;
Science Citation Index®;
Biotechnology Citation Index®;
Journal Citation Reports/Science Edition;
Derwent Drug File;